Short Answer

Both the model and the market expect a bill curbing pharmaceutical monopolies to become law before Jan 4, 2027, with no compelling evidence of mispricing.

1. Market Behavior & Drivers

This market has exhibited a sideways trend with minimal volatility, trading within a very narrow two-point range between 15.0% and 17.0%. These price points have served as the effective support and resistance levels for the market. The price began at 15.0% and experienced a minor increase to 17.0%, where it has remained. There have been no significant price spikes or drops to analyze, as the market has remained stable and confined within this tight band.
The total trading volume is extremely low, at only 29 contracts, which indicates a lack of market participation and low conviction from traders. This low engagement suggests that there has been no significant news or catalyst to drive interest or shift sentiment. The market's persistent low probability, currently at 17.0%, likely reflects the impact of existing legislation. Given that the Inflation Reduction Act of 2022 granted Medicare drug price negotiation authority and the Consolidated Appropriations Act, 2026 was signed into law with substantial reforms for Pharmacy Benefit Managers, the market sentiment appears to be that the impetus for passing another major bill on this topic before the 2027 deadline is low.
  • 2026 midterm elections may shift legislative control impacting regulations.
  • Congressional leaders appear to advocate for curbing pharmaceutical monopolies.
  • Procedural hurdles and late 2026 deadlines limit bill progress.
  • H.R. 3546 was introduced in the 119th Congress.
  • A market tracks the potential enactment of a new monopolies act.

Who Wins and Why

Outcome Market Model Why
Before Jan 4, 2027 17.0% 17.0% Legislation targeting pharmaceutical monopolies typically encounters strong industry opposition in Congress.

Current Context

Existing legislation addresses drug costs, though some reforms face delayed implementation. The Inflation Reduction Act (IRA) of 2022 granted Medicare authority to negotiate drug prices, with the first negotiated prices taking effect on January 1, 2026 [1]. Additionally, the Consolidated Appropriations Act, 2026 (CAA), signed into law on February 3, 2026, includes significant reforms for Pharmacy Benefit Managers (PBMs) [2][3]. These reforms mandate new requirements for rebate pass-through, enhanced disclosures, flat-fee service arrangements, and increased federal oversight [2][3]. However, many of these PBM reforms are scheduled to take effect in 2028-2029, which is beyond the specified January 4, 2027, deadline [2][3]. Some experts indicate that while these PBM reforms increase transparency, they might not fundamentally curb pharmaceutical monopolies and could even inadvertently strengthen pharmaceutical companies' pricing power by weakening PBMs' negotiation tools [4].
A new bipartisan bill targeting monopolies faces significant implementation challenges. The "Break Up Big Medicine Act," introduced in February 2026 by Senators Elizabeth Warren (D-Massachusetts) and Josh Hawley (R-Missouri), directly targets pharmaceutical monopolies and aims to address consolidation and vertical integration within the healthcare industry [5]. Specifically, the bill proposes to prohibit a parent company from simultaneously owning a medical provider or management services organization and a PBM or an insurer [5][3]. It also seeks to prevent prescription drug or medical device wholesalers from owning medical providers or management services organizations [5][3]. This bill is currently in its early stages, having been referred to committee with no announced hearing date as of May 2026, and many believe its chances of passing are "slim to none," especially following the passage of the Consolidated Appropriations Act of 2026 [2].
Sweeping changes, strong lobbying, and political hurdles impede the bill's passage. Reasons for this low likelihood include the bill's broad scope, which proposes sweeping structural changes to the healthcare industry and could lead to "epic destruction" of existing structures, including large insurance companies, PBMs, and wholesalers [2]. Furthermore, powerful pharmaceutical companies, insurers, and PBMs are expected to mount substantial lobbying efforts against such a comprehensive bill, consistent with historical spending to influence legislation [2]. Despite its bipartisan sponsorship, the bill is considered too extreme for many members of both parties. Congress may also prefer to observe the impact of the recently enacted PBM reforms before pursuing more drastic measures [2].
Sources (5)
  1. 1kalshi.com
  2. 2kalshi.com
  3. 3fastcompany.com
  4. 4kalshi.com
  5. 5covers.com

2. Price Chart

Historical Price (Probability)

Outcome probability
Date

3. Market Data

Contract Snapshot

The market resolves to "Yes" if a bill titled "Patients Before Monopolies Act," or an equivalent bill curbing monopolistic practices (specifically joint ownership of PBM and Pharmacy businesses) in healthcare or pharmaceuticals, becomes law. If no such bill becomes law by January 4, 2027, the market resolves to "No." The outcome will be verified from the Library of Congress, and the market closes early if the event occurs, with a projected payout 30 minutes after closing.

Available Contracts

Market options and current pricing

Outcome bucket Yes (price) No (price) Last trade probability
Before Jan 4, 2027 $0.15 $0.91 17%

Market Discussion

A bill aimed at curbing pharmaceutical monopolies is demonstrating significant bipartisan momentum in the U.S. Congress, with several measures advancing in the Senate Judiciary Committee [1]. These legislative efforts seek to address conflicts of interest, prevent "product hopping," and enhance transparency to foster competition, which could lead to lower drug costs and billions in taxpayer savings [1]. Despite historical challenges, there is a current sense of urgency for reforms within the 119th Congress, driven by widespread public discontent over high drug prices [2].

Sources (2)
  1. 1house.govharshbarger.house.gov
  2. 2forbes.com

4. Trust Index

Octagon Trust Index Kalshi 71 Good

Order book is critically thin.

Primary risk· Trade quality

How it adds up
Integrity80% of score82Good
Trade quality20% of score26Avoid

Includes the cost to trade: a $10,000 order can't be filled here because the order book is too thin.

Trust score71Good

Weighted blend with hard caps — a critically weak safety pillar, or a severe trading anomaly, caps the total regardless of the rest. Full methodology · About the Trust Index

Trust profile
Integrity4 screens run · 6 don't apply
Market integrity
77Good

Outcome is hard to influence

No suspicious activity on any screen

Screened clean
Large tradesTape too thin Clear
Thin-volume movesPrice moves carried real volume. Clear
Size patternsTape too thin Clear
2 screens not run
Outcome control · doesn't apply to this market type
Thin-leg conviction · doesn't apply to this market type
Info fairness
80Good

Structural prior — no screens apply

No suspicious activity on any screen

Screened clean
Information exposureNo concentrated group can know the outcome materially early. Clear
4 screens not run
Move vs. catalyst · doesn't apply to this market type
Longshot repricing · doesn't apply to this market type
Pre-broadcast certainty · doesn't apply to this market type
Cross-venue timing · doesn't apply to this market type
Resolution quality
92Strong

Resolution mechanism is dependable

No suspicious activity on any screen

Resolution rules read: Clear

Liquidity
34Very thin

Hard to fill near the screen price

1 contract

Before Jan 4, 202734
Very thin · low confidence

Light recent trading — size may not fill near the screen price.

Move quality
66Mostly confirmed

Most moves carried real volume

1 contract

Before Jan 4, 202766
Mostly confirmed · medium confidence

Volume is light/neutral for the move over 24h

Rule clarity
100Clear

Counts toward Resolution quality, not here

1 contract

Before Jan 4, 2027100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Trade quality
26Avoid

Order book is critically thin

Thin market — entering or exiting at fair value will be difficult.

Outcome quality 34 (notional-weighted)

$100 order: 22.9c slippage (~449% of a 5.1c contract)

$1,000 order: 66.8c slippage (~1,310% of a 5.1c contract)

$10,000 order: book too thin to fill

Before Jan 4, 202734Market scoreLiquidity34Move quality66Rule clarity100
Why 34
Liquidity
34 · Very thin · low confidence

Light recent trading — size may not fill near the screen price.

Move quality
66 · Mostly confirmed · medium confidence

Volume is light/neutral for the move over 24h

Rule clarity
100 · Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear

underwriting_v1.4 · computed Sep 23, 2026

5. How might the outcome of the 2026 midterm elections shift the legislative agenda for or against new pharmaceutical monopoly regulations before the 119th Congress adjourns?

2026 House ForecastLeaning Democratic (April 2026) [1][2][3]
2026 Senate ForecastRoughly a toss-up (April 2026) [1][2][3]
Drug Policy FocusDrug pricing and competition expected to remain a focus for both parties [1][4][5][6][7]
The 2026 midterm elections may significantly alter legislative control, potentially impacting new pharmaceutical monopoly regulations such as H.R. 3546 [1][4][5][6][7]. As of April 2026, forecasts indicate the House of Representatives is leaning Democratic, while the Senate remains a toss-up [1][2][3]. These shifts could lead to changes in committee leadership and influence the scheduling of high-profile drug policy bills [1].
Drug pricing and competition will remain a key legislative priority, regardless of which party controls Congress [1][4][5][6][7]. The increasing emphasis on affordability and transparency in healthcare ensures that issues like drug pricing, exclusivity, and competition will stay on the legislative agenda, though the specific methods for addressing them may differ based on the majority party [5][6][7]. For example, H.R. 3546 aims to reduce prescription drug prices by eliminating government-granted monopolies for manufacturers charging above-median prices, and it includes provisions for waiving exclusivities and issuing open licenses for "excessively priced" drugs [4].
Bipartisan consensus exists for certain pharmaceutical competition reforms within Congress [8][9][10]. This sustained support suggests that even if comprehensive "monopoly curbing" legislation faces obstacles, more focused measures aimed at fostering competition in patents and exclusivity are likely to advance before the 119th Congress adjourns [11][8][9][10].
Sources (11)
  1. 12026 Election Forecast: House, Senate & Governors | USPollingData | USPollingData.comuspollingdata.com
  2. 22026 Senate Election Forecast Maps - 270toWin270towin.com
  3. 32026 House Election Forecast Maps - 270toWin270towin.com
  4. 4https://www.congress.gov/119/bills/hr3546/BILLS-119hr3546ih.htmcongress.gov
  5. 5US healthcare policy outlook for the 2026 midterms: PwCpwc.com
  6. 6Health Policy Volatility, Regulatory Shifts Shape Outlook Ahead of 2026 Midterms | AJMCajmc.com
  7. 72026 Life Sciences Policy Outlook - Life Sciences, Biotechnology & Nanotechnology - United Statesmondaq.com
  8. 8Five Bipartisan Pharma Patent and Pricing Bills Shared in Senatenatlawreview.com
  9. 9https://www.govinfo.gov/link/bills/119/s/3716?link-type=pdfgovinfo.gov
  10. 10Durbin, Tillis Introduce Legislation To Improve Coordination Between USPTO and FDA On Pharma Patents | U.S. Senator Dick Durbin of Illinoisdurbin.senate.gov
  11. 11Will a bill curbing pharmaceutical monopolies become law? Odds & Predictions 2027kalshi.com

6. Beyond its bipartisan sponsors, what evidence of support or opposition for new monopoly curbs has emerged from leadership in the 119th Congress?

PBM Reform AdvocateSenate Majority Leader John Thune (R-SD) [1][2]
Drug Price Reduction ChampionSenator Bill Cassidy (R-LA) [3]
Opponent of Drug Cost LegislationSpeaker of the House Mike Johnson (R-LA) [4]
Several congressional leaders advocate for curbing pharmaceutical monopolies. Senate Majority Leader John Thune (R-SD) champions Pharmacy Benefit Manager (PBM) reform, promoting increased transparency and decoupling PBM compensation from drug list prices to reduce consumer costs [1][2]. Senator Bill Cassidy (R-LA), Chair of the Senate HELP Committee, has spearheaded policies to lower prescription drug prices and control healthcare middlemen, aiming for a balance between innovation and affordability [3][5][6]. Furthermore, Senator Chuck Grassley (R-IA) has contributed to drug pricing legislation, including the Drug Competition Enhancement Act [7], and Representative Pramila Jayapal (D-WA) co-chairs the "Monopoly Busters Caucus," which focuses on tackling corporate consolidation across various sectors, including healthcare [8][9][10][11].
Other leaders voice opposition to aggressive monopoly curbs. Speaker of the House Mike Johnson (R-LA) has opposed legislation designed to lower drug costs, specifically efforts for Medicare drug price negotiation and provisions of the Inflation Reduction Act [4]. He also expressed concerns regarding a White House-proposed crackdown on the pharmaceutical industry [12]. Representative Scott Fitzgerald (R-WI), who chairs the House Subcommittee on Administrative State, Regulatory Reform, and Antitrust, prioritizes reversing the "Biden Administration's anti-business agenda" and advocates for free-market competition. He cautions against "European style micromanagement" in antitrust policy, suggesting it could negatively impact industry profits and research and development [13][14][15][16][17][18].
Sources (18)
  1. 1senate.govrepublicanleader.senate.gov
  2. 2sdpha.org
  3. 3senate.govhelp.senate.gov
  4. 4protectourcare.org
  5. 5senate.govcassidy.senate.gov
  6. 6senate.govhelp.senate.gov
  7. 7senate.govgrassley.senate.gov
  8. 8house.govjayapal.house.gov
  9. 9house.govdeluzio.house.gov
  10. 10house.govcraig.house.gov
  11. 11knkx.org
  12. 12politico.com
  13. 13house.govfitzgerald.house.gov
  14. 14vitallaw.com
  15. 15youtube.com
  16. 16bgov.comabout.bgov.com
  17. 17bloomberglaw.comnews.bloomberglaw.com
  18. 18punchbowl.news

7. What procedural hurdles and timeline constraints within the 119th Congress could prevent a new, complex healthcare bill from reaching a floor vote before January 2027?

Senate Target AdjournmentDecember 18, 2026 [1]
House Target Last Session DayDecember 17, 2026 [2]
Floor Vote TargetBefore January 2027 [1]
Key legislative deadlines in late 2026 severely limit floor vote opportunities. A new, complex healthcare bill faces significant procedural hurdles and timeline constraints within the 119th Congress, making it challenging to reach a floor vote before January 2027. The Senate's target adjournment for its second session is December 18, 2026 [1]. Similarly, the House’s 2026 calendar sets its target last day of session for December 17, 2026 [2]. Any new, complex healthcare or pharmaceutical bill not ready for floor consideration by mid-to-late December is especially likely to miss a pre–January 2027 floor vote due to these tight windows [1].
Extensive procedural requirements pose significant obstacles for complex healthcare legislation. The 119th Congress mandates committee consideration and reporting before a bill can be scheduled for floor action, meaning a new, complex healthcare bill introduced too late in the session may not clear committees in time [3]. These complex policy packages commonly require multiple procedural steps across both chambers, including committee referral, hearings, markup, reporting, and then floor scheduling and debate with amendment management [3]. This extensive process increases the risk that such bills cannot be arranged into a floor timetable that resolves before early January 2027 [3]. For instance, legislation like H.R. 3546, which proposes ending government-granted monopolies for excessively priced drugs, exemplifies the typical complexity of "curbing monopolies" healthcare legislation [4]. Similarly, the bipartisan Durbin-Cassidy REMEDY Act, aimed at removing incentives for brand-name manufacturers to extend monopolies, indicates that such efforts require careful Senate procedural handling before becoming law [5].
Sources (5)
  1. 1https://www.senate.gov/legislative/resources/pdf/2026_calendar.pdfsenate.gov
  2. 22026 House Calendar | House Press Gallerypressgallery.house.gov
  3. 3The Legislative Process: Committee Consideration (Video)congress.gov
  4. 4https://www.congress.gov/119/bills/hr3546/BILLS-119hr3546ih.htmcongress.gov
  5. 5Durbin, Cassidy REMEDY Act To Lower Prescription Costs By Promoting Generic Competition | U.S. Senator Dick Durbin of Illinoisdurbin.senate.gov

8. What Could Change the Odds

Key Catalysts

A market on Kalshi, titled "Will a bill curbing pharmaceutical monopolies become law? Odds & Predictions 2027," is tracking the potential enactment of a "Patients Before Monopolies Act" [1]. This market is framed around a 2027 outcome, not reflecting confirmed enactment [1].
Another potential catalyst is the introduction of H.R. 3546 (119th Congress) on May 21, 2025 [2]. This bill proposes to end "government-granted monopolies" for drug manufacturers charging excessively priced drugs [2]. The proposal includes waiving or voiding government-granted exclusivities and granting open, non-exclusive licenses once the Secretary determines a brand-name drug is "excessively priced" [2].

Key Dates & Catalysts

  • Expiration: January 04, 2027
  • Closes: January 04, 2027
Sources (2)
  1. 1Will a bill curbing pharmaceutical monopolies become law? Odds & Predictions 2027kalshi.com
  2. 2https://www.congress.gov/119/bills/hr3546/BILLS-119hr3546ih.htmcongress.gov